Etubics Corporation, based in Seattle, Wash., is a next generation clinical stage bio-pharmaceutical company. The Company is developing the next generation in vaccines and immunotherapies, utilizing a patented advanced generation adenovirus delivery platform and a validated manufacturing human cell line, collectively the Etubics Platform.
The Company’s products have been developed to overcome three significant limitations associated with existing adenovirus based products: i) ineffectiveness in the presence of pre-existing immunity; ii) inability to immunize multiple times against the same disease; and, iii) inability to immunize against multiple diseases in the same person.
Benefits of the Etubics Platform products include the following:
• Safe and Thoroughly Studied including human trials
• Effective in the Presence of Pre-Existing Immunity
• CMI Response
• Rapid Development
• Diverse Product Opportunities
The Company has completed Phase I/IIa clinical trials with its lead product, ETBX-011 an immunotherapeutic to treat colorectal cancer. To date, the Company has been very encouraged by the clinical data for ETBX-011 and no safety issues or serious adverse effects (SAE) have been reported in both animal and human studies.
Company Details
- Employees
- 7
- Founded
- 2005
- Address
- 410 West Harrison Street,
- Phone
- 2068382978
- ge****@****ics.com
- Industry
- Biotechnology
- Website
- etubics.com
- Keywords
- Oceanside.
- HQ
- Seattle, Wash.
Etubics Questions
Etubics's helpline number is 2068382978
Etubics's website is etubics.com
Etubics's LinkedIn profile is https://www.linkedin.com/company/etubics
Etubics has
7 employees.
View email and phone details for 7
employees at Etubics.
Etubics's industry is
Biotechnology
Etubics's top competitors are
Capo Therapeutics, Inc.,
Conserv Bioscience,
_,
20med Therapeutics,
Elarex,
Tapimmune Inc,
Genetic Immunity®️,
Anp Technologies, Inc.,
Vetkart,
Redbiotec Ag.
Etubics's support email address is general@etubics.com
Etubics's categories are Biotechnology
Etubics's founding year is 2005
